Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by tissue sample) with advanced high-grade serous or endometrioid cancer of the ovary, fallopian tube, or peritoneum.
• People whose cancer has come back or gotten worse within 6 months of receiving platinum-based chemotherapy, or whose cancer progressed during their first course of platinum treatment, or who cannot tolerate standard treatment or have no suitable standard treatment available according to their doctor.
• People with a life expectancy of more than 3 months.
• People who are generally well enough to carry out light activity and care for themselves (a measure doctors use called ECOG performance status of 0 or 1).
• People whose cancer can be measured on scans using standard criteria (called RECIST v1.1).

Who may not be able to join:

• People who have received any anti-cancer treatment within 28 days (or within 5 half-lives of that treatment) before starting the trial drug.
• People who have previously been treated with a group B adenovirus-based therapy.
• People who are currently in another clinical trial or have received another experimental medicine within 5 half-lives before starting the trial drug.
• People who have had radiation therapy within 2 weeks before starting the trial drug, or who are planned to have radiation therapy during the trial.
• People who have signs of cancer spread to the brain or nervous system. People with a previous history of brain metastases may be considered only if there is no sign of the cancer growing or bleeding after treatment (confirm with trial site).
• People who have uncontrolled fluid build-up around the lungs or heart that requires draining once a month or more often.
• People who have previously had lung inflammation (pneumonitis) or a condition called interstitial lung disease.
• People who have a specific heart rhythm abnormality on a screening heart tracing (ECG), or a history of certain inherited or acquired heart rhythm conditions (confirm with trial site).
• People who are currently taking medications known to affect heart rhythm in a way that increases risk of a serious condition called Torsades de Pointes.
• People with an active hepatitis infection (hepatitis B or C), or a past history of hepatitis B infection (confirm with trial site).
• People with an active tuberculosis infection.
• People with an active COVID-19 (SARS-CoV-2) infection.
• People with an active HIV infection or a known history of HIV infection.
• People who have needed intravenous antibiotics for an infection within 2 weeks before starting the trial drug, or who are on long-term antibiotic tablets for an ongoing infection.
• People who are known to be allergic or have a sensitivity to the ingredients in the trial drug.
• People who have had a viral infection in the 2 weeks before starting the trial drug.
• People with an active autoimmune disease that has needed systemic (whole-body) treatment in the past 2 years.
• People with a known risk of kidney injury, including those with a history of kidney disease.
• People with known heart failure classified as moderate to severe (NYHA Class 2–4).
• People who are known to be allergic or sensitive to paracetamol (acetaminophen), which is used alongside the trial drug.
• People who regularly drink more than 2 units of alcohol per day.
• People with certain heart conditions, including reduced heart pumping function (below 50%), unstable angina, serious uncontrolled irregular heartbeat, a heart attack within the past 6 months, or a history of heart muscle inflammation (myocarditis).
• People whose blood oxygen level is below 92% while breathing normal room air before starting the trial drug.
• People who have received any licensed or experimental vaccine within 28 days before starting the trial drug.

Important: Always verify eligibility with the trial site directly before applying.